Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vitamin D Deficiency 1Triple Negative Breast Neoplasms 1Polycystic Ovary Syndrome 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × Vitamins × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡